microRNAs: critical targets for treating rheumatoid arthritis angiogenesis.

Vascular neogenesis, an early event in the development of rheumatoid arthritis (RA) inflammation, is critical for the formation of synovial vascular networks and plays a key role in the progression and persistence of chronic RA inflammation. microRNAs (miRNAs), a class of single-stranded, non-coding RNAs with approximately 21-23 nucleotides in length, regulate gene expression by binding to the 3' untranslated region (3'-UTR) of specific mRNAs. Increasing evidence suggests that miRNAs are differently expressed in diseases associated with vascular neogenesis and play a crucial role in disease-related vascular neogenesis. However, current studies are not sufficient and further experimental studies are needed to validate and establish the relationship between miRNAs and diseases associated with vascular neogenesis, and to determine the specific role of miRNAs in vascular development pathways. To better treat vascular neogenesis in diseases such as RA, we need additional studies on the role of miRNAs and their target genes in vascular development, and to provide more strategic references. In addition, future studies can use modern biotechnological methods such as proteomics and transcriptomics to investigate the expression and regulatory mechanisms of miRNAs, providing a more comprehensive and in-depth research basis for the treatment of related diseases such as RA.

Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions.

OBJECTIVE: To investigate using detection of human papillomavirus (HPV) L1 capsid protein to predict the course of mild or moderate cervical intraepithelial neoplasia (CIN). STUDY DESIGN: Immunocytochemical analysis using antibody against HPV L1 capsid protein was carried out on 274 Pap tests from women positive for high-risk HPV detected by hybrid capture, with cytologic diagnoses of atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), atypical squamous cell cannot exclude high-grade squamous intraepithelial lesion (HSIL) (ASC-H), HSIL and squamous cell carcinoma (SCC). Histologic diagnosis was available for patients after initial cytologic diagnosis. RESULTS: L1 capsid protein was positive in 69.79% of cervicitis, 83.53 % of CIN 1, 41.81% of CIN2, 3.13% of CIN3 and 0% of SCC. Cytologic diagnosis revealed a higher expression rate in LSIL than in ASCUS and HSIL + SCC. In 71 ASCUS/LSIL without treatment, no L1-positive cases progressed in cytology; 18.75% of L1-negative cases progressed to ASC-H/HSIL. CONCLUSION: The decreased expression of HPV L1 may correlate with progressed cytopathology. The expressions of HPV L1 in liquid-based cell specimens implied the histopathology diag- nosis of cervix. Expression of HPV L1 may have significance in treating ASCUS and LSIL.

New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery.

Because the brainstem has little functional redundancy, diffuse lesions have been regarded as inoperable. To determine whether local drug therapy can prolong survival in a rodent model of a tumor in such eloquent tissue, lethal doses of F98 and 9L tumor cells were injected into the brainstems of Fischer 344 rats. Five days after inoculations, 0.5 mg/ml solutions of carboplatin were infused at 1 microl/h for 7 days. Compared to control groups that survived 13-17 days with F98 tumors and 22-23 days with 9L tumors, animals locally infused with 0.1 mg of carboplatin survived 27-30 days (Prob > Chi Sq = 0.0003), and 32 days (Prob > Chi Sq = 0.01), respectively. Measurements of tissue platinum levels at autopsy suggested that infusions distributed pharmacologically relevant levels of carboplatin through a volume of tissue at least 0.5 cm in diameter. The results suggest that chronic low-flow infusions provide a promising approach to therapy for CNS lesions in tissues considered to be inoperable.